HomeSmall Caps
Share

Shares of a biotech company backed by AstraZeneca plummeted following the FDA's rejection. Should you sell?

Maria Dranishnikova

Maria Dranishnikova

Oninvest reporter
Summit announced that the FDA had refused to approve its drug, ivonesimab, in combination with chemotherapy for the treatment of non-small-cell lung cancer / Photo: Shutterstock.com

Summit announced that the FDA had refused to approve its drug, ivonesimab, in combination with chemotherapy for the treatment of non-small-cell lung cancer / Photo: Shutterstock.com

Shares of biotech company Summit Therapeutics plummeted more than 16% on the Nasdaq on November 16—hitting a two-year low. The company reported that the U.S. Food and Drug Administration (FDA) had denied its application to register a lung cancer treatment. In September 2026, pharmaceutical giant AstraZeneca announced plans to invest $2 billion in Summit.

Details

Summit shares plummeted more than 16% on the Nasdaq on November 16, falling to $11.82. This marks the lowest closing price in more than two years.

The stock price plummeted after the company announced that the FDA had refused to approve its drug, ivonesimab, intended for the treatment of non-small-cell lung cancer in combination with chemotherapy.

The current data did not convince the regulator that the therapy actually helps patients live longer, according to a press release. The combination of ivonescimab and chemotherapy reduced the risk of disease progression or death by 48% compared with chemotherapy alone.

However, the FDA noted the absence of a statistically significant improvement in overall survival—the length of time patients live after starting treatment. This metric is considered the “gold standard” in clinical trials because death is a clear, unambiguous event that is not subject to bias, Barron’s explains. The company did not provide any details in the press release regarding the timeline or plans for resubmission.

What Makes This Development Project Interesting

Ivonescimab is a bispecific antibody. Unlike conventional antibodies, it targets two proteins at once: PD-1, which helps cancer cells evade the immune system, and VEGF, which tumors use to grow blood vessels. In 2022, Summit acquired exclusive rights from the Chinese company Akeso to develop and commercialize the drug in the United States, Canada, Europe, and Japan. In June 2024, the license was expanded to include Latin America, the Middle East, and Africa. Akeso retained the rights to the drug in the rest of the world and has been marketing it in China since 2024.

In late September, on the eve of the FDA’s decision, AstraZeneca entered into an agreement with Summit under which it planned to invest $2 billion in the company and collaborate on research into combinations of ivonescimab with other drugs. If ivonescimab were approved, AstraZeneca could benefit from its launch in the U.S. market thanks to its stake in Summit, Barron’s reported.

What Analysts Are Saying

After the FDA refused to approve ivonescimab, at least three analysts—Evercore ISI Group, Barclays, and Citigroup—lowered their price targets for the company’s stock, according to Yahoo Finance. Barclays cut its price target more sharply than the others—by 10%, to $18 (52% upside potential)—and maintains a “Hold” (Equal Weight) rating on the biotech stock.

Citi analyst Igale Noh-Amovitz called the FDA’s decision “widely anticipated” on Wall Street, according to Barron’s. Investors were disappointed, rather, by the overall outlook for the class of drugs to which Summit’s therapy belongs. Citi recommends buying Summit shares with a price target of $42 (255% upside potential), down from the previous $43.

In total, Summit shares have 12 “buy” ratings from Wall Street analysts and six “hold” ratings. The average price target is $29.71, which is 151% higher than the last closing price.

Share

Trending

Stock Screener
Buy
Sell
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Small Caps
Investment and Finance News